JP2013501762A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501762A5
JP2013501762A5 JP2012524262A JP2012524262A JP2013501762A5 JP 2013501762 A5 JP2013501762 A5 JP 2013501762A5 JP 2012524262 A JP2012524262 A JP 2012524262A JP 2012524262 A JP2012524262 A JP 2012524262A JP 2013501762 A5 JP2013501762 A5 JP 2013501762A5
Authority
JP
Japan
Prior art keywords
floating granule
floating
granule according
group
alkaline agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012524262A
Other languages
English (en)
Japanese (ja)
Other versions
JP6068142B2 (ja
JP2013501762A (ja
Filing date
Publication date
Priority claimed from FR0955641A external-priority patent/FR2949061B1/fr
Application filed filed Critical
Publication of JP2013501762A publication Critical patent/JP2013501762A/ja
Publication of JP2013501762A5 publication Critical patent/JP2013501762A5/ja
Application granted granted Critical
Publication of JP6068142B2 publication Critical patent/JP6068142B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012524262A 2009-08-12 2010-08-11 浮遊微粒剤 Expired - Fee Related JP6068142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0955641A FR2949061B1 (fr) 2009-08-12 2009-08-12 Microgranules flottants
FR0955641 2009-08-12
PCT/FR2010/051691 WO2011018582A2 (fr) 2009-08-12 2010-08-11 Microgranulés flottants

Publications (3)

Publication Number Publication Date
JP2013501762A JP2013501762A (ja) 2013-01-17
JP2013501762A5 true JP2013501762A5 (enExample) 2015-06-11
JP6068142B2 JP6068142B2 (ja) 2017-01-25

Family

ID=42115979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012524262A Expired - Fee Related JP6068142B2 (ja) 2009-08-12 2010-08-11 浮遊微粒剤

Country Status (34)

Country Link
US (1) US8916202B2 (enExample)
EP (1) EP2464333B1 (enExample)
JP (1) JP6068142B2 (enExample)
KR (2) KR20120050477A (enExample)
CN (1) CN102548541B (enExample)
AR (1) AR077864A1 (enExample)
AU (1) AU2010283608B9 (enExample)
BR (1) BR112012003289B1 (enExample)
CA (1) CA2771053C (enExample)
CL (1) CL2012000376A1 (enExample)
CY (1) CY1118119T1 (enExample)
DK (1) DK2464333T3 (enExample)
EA (1) EA023532B1 (enExample)
ES (1) ES2588430T3 (enExample)
FR (1) FR2949061B1 (enExample)
HR (1) HRP20161149T1 (enExample)
HU (1) HUE030027T2 (enExample)
IL (1) IL218072A (enExample)
IN (1) IN2012DN01864A (enExample)
LT (1) LT2464333T (enExample)
MA (1) MA33523B1 (enExample)
MX (1) MX2012001878A (enExample)
NZ (1) NZ598468A (enExample)
PE (1) PE20120805A1 (enExample)
PL (1) PL2464333T3 (enExample)
PT (1) PT2464333T (enExample)
SG (1) SG180305A1 (enExample)
SI (1) SI2464333T1 (enExample)
SM (1) SMT201600347B (enExample)
TN (1) TN2012000068A1 (enExample)
TW (1) TWI478731B (enExample)
UA (1) UA107361C2 (enExample)
WO (1) WO2011018582A2 (enExample)
ZA (1) ZA201201711B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
WO2015102629A1 (en) 2014-01-02 2015-07-09 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2989297A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
CA2986545C (en) 2015-07-24 2019-09-03 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
IL275312B2 (en) 2017-12-18 2024-09-01 Tris Pharma Inc Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP2021506984A (ja) * 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (ja) 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CN1688292A (zh) 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 掩味剂型及其制造方法
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
PT1931315E (pt) * 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
WO2007075980A2 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Similar Documents

Publication Publication Date Title
JP2013501762A5 (enExample)
JP2012508784A5 (enExample)
NZ598468A (en) Floating microgranules
HRP20191911T1 (hr) Granule gama-hidroksibutirične kiseline
ES2307463T3 (es) Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina.
CA2952406A1 (en) Solid formulation and method for preventing or reducing coloration thereof
JP2005508959A5 (enExample)
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
JP2006298933A5 (enExample)
CA2952405A1 (en) Solid formulation and method for stabilizing the same
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
WO2013093630A3 (en) Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
WO2008020286A3 (en) Pharmaceutical compositions of duloxetine
JP2005538104A5 (enExample)
JP2014005302A5 (enExample)
JP2013529072A5 (enExample)
HRP20171384T1 (hr) Farmaceutski pripravak
WO2008114800A8 (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
JP2011037832A5 (enExample)
EP2490676A2 (en) Pharmaceutical compositions of pde-5 inhibitors and dapoxetine
WO2009047802A3 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
JP2007509891A5 (enExample)
WO2007072495A3 (en) Coated tablets having prolonged gastric retention
JP2004531399A5 (enExample)
HRP20120049T1 (hr) Farmaceutski dozirni oblik koji obuhvaća pilule kao i postupak njegove proizvodnje